Markers of Acute Kidney Injury to be Monitored in Forthcoming Clinical Trials

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) February 27, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function announced that it has expanded its clinical advisory board to include John Kellum, MD–noted critical care physician and acute kidney injury expert at the University of Pittsburgh Medical Center.

John Kellum, M.D. is a clinician scientist whose research interests span various aspects of Critical Care Medicine, but center in critical care nephrology (including acid-base, and renal replacement therapy), sepsis and multi-organ failure (including blood purification), and clinical epidemiology. His research has received continuous funding from the National Institutes of Health since 2001, and he has active funding from multiple different NIH Institutes. Dr. Kellum has authored more than 300 publications and has also edited several major textbooks including Critical Care Nephrology and Stewart’s Textbook of Acid-Base.

Read the full press release here:John Kellum Clinical Advisor